FIRST ADDENDUM TO
LICENSE AND DEVELOPMENT AGREEMENT
FOR SPECIFIC MEDICAL TECHNOLOGY
FOR THE DETECTION OF ONCOGENIC HPV VIRUS
This is a First Addendum to the License and Development Agreement for Specific Medical Technology for the
Detection of Oncogenic HPV Virus dated June 23, 2000 ("License and Development Agreement") by and
between INVIRION, a United States corporation organized and existing under the laws of the State of Illinois,
having a place of business at 2350 Pilgrim Highway, Frankfort, Michigan 49635 ("Invirion") and AMPERSAND
MEDICAL CORPORATION, a Delaware corporation, having a place of business at 414 North Orleans,
Chicago, Illinois 60610 ("Ampersand").
Except to the extent modified by this First Addendum, the License and Development Agreement is hereby
The License and Development Agreement is hereby modified by incorporating into it the following agreement
between the parties:
1. The $100,000 payment for the License and Development Agreement (now past due) and $150,000 payment
now due as a result of Invirion meeting the benchmark set forth in Paragraph 3.1(2), shall not be made payable
immediately, but rather, converted into ten (10) installment payments of $25,000 per month with the first payment
due on September 11, 2000.
2. In exchange for the change in payment terms, Ampersand agrees to the following:
a. On September 11, 2000 Ampersand will issue to Invirion the warrant for 150,000 shares of Ampersand stock
as set forth in Exhibit B and also issue to Invirion a similar warrant for 100,000 additional shares of Ampersand
b. The timeline for steps 4-7 set forth in Exhibit AD shall be extended to ten months from September 11, 2000.
c. The timeline for steps 8-11 set forth in Exhibit AD shall be extended to 14 months from September 11, 2000.
d. In the event the License and Development Agreement is terminated, all payments made to Invirion and all
warrants issued to Invirion are non-refundable and all warrants are irrevocable an